Cargando…

Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients

OBJECTIVE: Pre-S1 antigen (pre-S1) is a component of hepatitis B virus large surface antigen (L-HBsAg). This study aimed to investigate the association between clinical pre-S1 antigen (pre-S1) status and adverse prognostic events in chronic hepatitis B (CHB) patients. METHODS: This study retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xingxin, Gu, Chenjian, Wei, Qian, Cao, Yirong, She, Weimin, Shi, Hong, Xie, Youhua, Guo, Jinsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105577/
https://www.ncbi.nlm.nih.gov/pubmed/37069959
http://dx.doi.org/10.2147/JHC.S373333
_version_ 1785026240581730304
author Zhang, Xingxin
Gu, Chenjian
Wei, Qian
Cao, Yirong
She, Weimin
Shi, Hong
Xie, Youhua
Guo, Jinsheng
author_facet Zhang, Xingxin
Gu, Chenjian
Wei, Qian
Cao, Yirong
She, Weimin
Shi, Hong
Xie, Youhua
Guo, Jinsheng
author_sort Zhang, Xingxin
collection PubMed
description OBJECTIVE: Pre-S1 antigen (pre-S1) is a component of hepatitis B virus large surface antigen (L-HBsAg). This study aimed to investigate the association between clinical pre-S1 antigen (pre-S1) status and adverse prognostic events in chronic hepatitis B (CHB) patients. METHODS: This study retrospectively enrolled 840 CHB patients with comprehensive clinical data, including 144 patients with multiple follow-up of pre-S1 status. All patients were tested for serum pre-S1 and divided into pre-S1 positive and negative groups. Single factor and logistic multiple regression analyses were performed to explore the association between pre-S1 and other HBV biomarkers with the risk of hepatocellular carcinoma (HCC) in CHB patients. The pre-S1 region sequences of HBV DNA were obtained from one pre-S1 positive and two pre-S1 negative treatment-naïve patients using polymerase chain reaction (PCR) amplification followed by Sanger sequencing. RESULTS: The quantitative HBsAg level was significantly higher in the pre-S1 positive group than that in the pre-S1 negative group (Z=−15.983, P<0.001). The positive rate of pre-S1 increased significantly with the increase in HBsAg level (χ(2)=317.963, P<0.001) and HBV DNA load (χ(2)=15.745, P<0.001). The pre-S1 negative group had a higher HCC risk than the pre-S1 positive group (Z=−2.00, P=0.045, OR=1.61). Moreover, patients in the sustained pre-S1 negative group had a higher HCC risk (Z=−2.56, P=0.011, OR=7.12) than those in the sustained pre-S1 positive group. The sequencing results revealed mutations in the pre-S1 region from samples of pre-S1 negative patients, including frameshift and deletion mutations. CONCLUSION: Pre-S1 is a biomarker that indicates the presence and replication of HBV. Pre-S1 sustained negativity attributed to pre-S1 mutations in CHB patients may be associated with a higher risk of HCC, which has clinical significance and warrant further investigations.
format Online
Article
Text
id pubmed-10105577
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101055772023-04-16 Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Zhang, Xingxin Gu, Chenjian Wei, Qian Cao, Yirong She, Weimin Shi, Hong Xie, Youhua Guo, Jinsheng J Hepatocell Carcinoma Original Research OBJECTIVE: Pre-S1 antigen (pre-S1) is a component of hepatitis B virus large surface antigen (L-HBsAg). This study aimed to investigate the association between clinical pre-S1 antigen (pre-S1) status and adverse prognostic events in chronic hepatitis B (CHB) patients. METHODS: This study retrospectively enrolled 840 CHB patients with comprehensive clinical data, including 144 patients with multiple follow-up of pre-S1 status. All patients were tested for serum pre-S1 and divided into pre-S1 positive and negative groups. Single factor and logistic multiple regression analyses were performed to explore the association between pre-S1 and other HBV biomarkers with the risk of hepatocellular carcinoma (HCC) in CHB patients. The pre-S1 region sequences of HBV DNA were obtained from one pre-S1 positive and two pre-S1 negative treatment-naïve patients using polymerase chain reaction (PCR) amplification followed by Sanger sequencing. RESULTS: The quantitative HBsAg level was significantly higher in the pre-S1 positive group than that in the pre-S1 negative group (Z=−15.983, P<0.001). The positive rate of pre-S1 increased significantly with the increase in HBsAg level (χ(2)=317.963, P<0.001) and HBV DNA load (χ(2)=15.745, P<0.001). The pre-S1 negative group had a higher HCC risk than the pre-S1 positive group (Z=−2.00, P=0.045, OR=1.61). Moreover, patients in the sustained pre-S1 negative group had a higher HCC risk (Z=−2.56, P=0.011, OR=7.12) than those in the sustained pre-S1 positive group. The sequencing results revealed mutations in the pre-S1 region from samples of pre-S1 negative patients, including frameshift and deletion mutations. CONCLUSION: Pre-S1 is a biomarker that indicates the presence and replication of HBV. Pre-S1 sustained negativity attributed to pre-S1 mutations in CHB patients may be associated with a higher risk of HCC, which has clinical significance and warrant further investigations. Dove 2023-04-11 /pmc/articles/PMC10105577/ /pubmed/37069959 http://dx.doi.org/10.2147/JHC.S373333 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Xingxin
Gu, Chenjian
Wei, Qian
Cao, Yirong
She, Weimin
Shi, Hong
Xie, Youhua
Guo, Jinsheng
Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title_full Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title_fullStr Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title_full_unstemmed Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title_short Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
title_sort pre-s1 mutations as indicated by serum pre-s1 antigen negative is associated with an increased risk of hepatocellular carcinoma in chronic hepatitis b patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105577/
https://www.ncbi.nlm.nih.gov/pubmed/37069959
http://dx.doi.org/10.2147/JHC.S373333
work_keys_str_mv AT zhangxingxin pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT guchenjian pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT weiqian pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT caoyirong pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT sheweimin pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT shihong pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT xieyouhua pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients
AT guojinsheng pres1mutationsasindicatedbyserumpres1antigennegativeisassociatedwithanincreasedriskofhepatocellularcarcinomainchronichepatitisbpatients